New Report Covers Fallopian Tube Cancer - Pipeline Review, H2 2016
Fallopian Tube Cancer - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.
Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis, which is present in up to two-thirds of patients. Usually, cancer metastasizes from other parts of the body such as the ovaries or endometrium to the fallopian tubes. Fallopian tube cancer treatment depends on age, the desire to have children, type and stage of the tumor. It usually involves surgery followed by chemotherapy.
Report Highlights
This report provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
To access full report with TOC, please visit Fallopian Tube Cancer - Pipeline Review, H2 2016
The Fallopian Tube Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Unknown stages are 1, 2, 12, 51, 25, 1, 1, 8 and 1 respectively for Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 3 and 1 molecules, respectively for Fallopian Tube Cancer.
Fallopian Tube Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)
- The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AbbVie Inc Acetylon Pharmaceuticals, Inc. Adaptimmune Therapeutics Plc Aduro BioTech, Inc. Advenchen Laboratories, LLC Amgen Inc. Astex Pharmaceuticals, Inc. AstraZeneca Plc Atara Biotherapeutics, Inc. Bayer AG Boehringer Ingelheim GmbH Boston Biomedical, Inc. Celldex Therapeutics, Inc. Celsion Corporation Cerulean Pharma, Inc. Clovis Oncology, Inc. Critical Outcome Technologies Inc. CTI BioPharma Corp. Dr. Reddy's Laboratories Limited EirGenix Inc. Eisai Co., Ltd. Eli Lilly and Company Esperance Pharmaceuticals, Inc. Exelixis, Inc. F. Hoffmann-La Roche Ltd. Galena Biopharma, Inc. Ganymed Pharmaceuticals AG Gene Techno Science Co., Ltd. Genentech, Inc. Genor BioPharma Co Ltd Glycotope GmbH Gradalis Inc. Ignyta, Inc. Immune Design Corp. ImmunoGen, Inc. Immunovaccine, Inc. Incyte Corporation Innate Pharma S.A. Johnson & Johnson Juno Therapeutics Inc. Karyopharm Therapeutics, Inc. Kyowa Hakko Kirin Co., Ltd. Lee's Pharmaceutical Holdings Limited Mabion SA MabVax Therapeutics Holdings, Inc. Mateon Therapeutics Inc MedImmune, LLC Medivation, Inc. Merck & Co., Inc. Merck KGaA Millennium Pharmaceuticals Inc MolMed S.p.A. Mycenax Biotech Inc. Novartis AG OBI Pharma, Inc. Oncobiologics, Inc. Oncolix, Inc. Oncolytics Biotech Inc. OncoMed Pharmaceuticals, Inc. Ono Pharmaceutical Co., Ltd. Oxford BioMedica Plc Pharma Mar, S.A. PsiOxus Therapeutics Limited Quest PharmaTech Inc. Richter Gedeon Nyrt. Samyang Holdings Corporation Sanofi Pasteur SA Sellas Inc Shenzen SiBiono GeneTech Co., Ltd. Sotio a.s. TapImmune Inc. Tara Immuno-Oncology Therapeutics LLC Tesaro, Inc. TetraLogic Pharmaceuticals Tyrogenex, Inc. Vascular Biogenics Ltd. VentiRx Pharmaceuticals, Inc. Vyriad Inc
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 04:04
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home